» Articles » PMID: 27286897

The Cryo-EM Structure of the Plasmodium Falciparum 20S Proteasome and Its Use in the Fight Against Malaria

Overview
Journal FEBS J
Specialty Biochemistry
Date 2016 Jun 12
PMID 27286897
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Plasmodium falciparum is the parasite responsible for the most severe form of malaria. Its increasing resistance to existing antimalarials represents a major threat to human health and urges the development of new therapeutic strategies to fight malaria. The proteasome is a protease complex essential in all eukaryotes. Accordingly, inhibition of the Plasmodium 20S proteasome is highly toxic for the parasite at all of its infective and developmental stages. Proteasome inhibitors have antimalarial potential both as curative and transmission blocking agents, but in order to have therapeutic application, they must specifically target the Plasmodium proteasome and not its human counterpart. X-ray crystallography has been widely used to determine structures of yeast and mammalian 20S proteasomes with ligands. However, crystallisation of the Plasmodium proteasome is challenging, as only small quantities of the complex can be directly purified from the parasite. Furthermore, most X-ray structures of proteasome-inhibitor complexes require soaking of crystals with high concentrations of ligand, thus preventing analysis of inhibitor subunit specificity. Instead we chose to determine the Plasmodium falciparum 20S proteasome structure, in the presence of a new rationally designed parasite-specific inhibitor, by high-resolution electron cryo-microscopy and single particle analysis. The resulting map, at a resolution of about 3.6 Å, allows a direct molecular analysis of inhibitor/enzyme interactions. Here we present an overview of this structure, and how it provides valuable information that can be used to assist in the design of improved proteasome inhibitors with the potential to be developed as next-generation antimalarial drugs.

Citing Articles

Characterization of Complexes and Supramolecular Structures by Electron Microscopy.

Carrascosa J Adv Exp Med Biol. 2024; 3234:191-205.

PMID: 38507208 DOI: 10.1007/978-3-031-52193-5_13.


Mutation in the 26S proteasome regulatory subunit gene in confers resistance to artemisinin.

Goncalves A, Lima-Pinheiro A, Teixeira M, Cassiano G, Cravo P, Ferreira P Front Cell Infect Microbiol. 2024; 14:1342856.

PMID: 38404287 PMC: 10884193. DOI: 10.3389/fcimb.2024.1342856.


Parasite proteostasis and artemisinin resistance.

Rosenthal M, Ng C Res Sq. 2023; .

PMID: 37292709 PMC: 10246279. DOI: 10.21203/rs.3.rs-2926003/v1.


Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.

Zhang H, Ginn J, Zhan W, Liu Y, Leung A, Toita A J Med Chem. 2022; 65(13):9350-9375.

PMID: 35727231 PMC: 10152543. DOI: 10.1021/acs.jmedchem.2c00611.


Structural parasitology of the malaria parasite Plasmodium falciparum.

Anton L, Cobb D, Ho C Trends Biochem Sci. 2021; 47(2):149-159.

PMID: 34887149 PMC: 11236216. DOI: 10.1016/j.tibs.2021.10.006.


References
1.
Ashley E, Dhorda M, Fairhurst R, Amaratunga C, Lim P, Suon S . Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014; 371(5):411-23. PMC: 4143591. DOI: 10.1056/NEJMoa1314981. View

2.
Beck P, Dubiella C, Groll M . Covalent and non-covalent reversible proteasome inhibition. Biol Chem. 2012; 393(10):1101-20. DOI: 10.1515/hsz-2012-0212. View

3.
Li H, ODonoghue A, van der Linden W, Xie S, Yoo E, Foe I . Structure- and function-based design of Plasmodium-selective proteasome inhibitors. Nature. 2016; 530(7589):233-6. PMC: 4755332. DOI: 10.1038/nature16936. View

4.
Ciechanover A . Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Bioorg Med Chem. 2013; 21(12):3400-10. DOI: 10.1016/j.bmc.2013.01.056. View

5.
Grant T, Grigorieff N . Measuring the optimal exposure for single particle cryo-EM using a 2.6 Å reconstruction of rotavirus VP6. Elife. 2015; 4:e06980. PMC: 4471936. DOI: 10.7554/eLife.06980. View